Horizon Funds Horizon Flexible Income ETF (BATS: FLXN)

Ultime notizie per Horizon Funds Horizon Flexible Income ETF (BATS:FLXN)

Flexion Therapeutics

To achieve its investment objective by investing primarily in non-investment grade (commonly referred to as high yield or junk) Fixed Income Instruments. The Funds Fixed Income Instruments may include debt or debt-related securities, income producing securities, and other instruments or evidences of indebtedness, including bonds, bills, notes (including structured notes), loans, money market instruments, mortgage and asset backed securities, and preferred stocks, and derivative instruments (including options) related thereto, and (ii) other investment companies that invest primarily in the foregoing instruments. While the Fund may invest in any Fixed Income Instruments, it expects to invest primarily in ETFs and options. There is no limitation on the maturity of Fixed Income Instruments in which the Fund may invest.

Horizon Flexible Income ETF

Horizon Funds Horizon Flexible Income ETF

Horizon, a company offering tailored investment and technology solutions to financial advisors, is introducing two new actively managed ETFs: Horizon Core Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BNDY#BATS">BNDY</a>) and Horizon Flexible Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#BATS">FLXN</a>). This expansion continues the company&#8217;s growth in its fast-growing <a href="https://www.benzinga.com/etfs">ETF family.</a>
Both are structured to assist advisors in producing a steady income while managing risk using options overlays, a strategy that is growing in popularity due to interest rate uncertainty and volatile credit markets.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46277766/tesla-troubles-amplified-by-musks-party-politics-etfs-on-edge">Tesla Troubles Amplified By Musk&#8217;s Party Politics: ETFs On Edge</a>
BNDY focuses on investment-grade fixed-income instruments across a range of maturities like government and corporate bonds, and adds put spread overlays to enhance return potential and buffer volatility. The fund carries an expense ratio of 0.65%.
FLXN, on the other hand, ventures into the high-yield debt space, providing flexibility to adjust holdings based on market conditions, once more employing put spread overlays to cushion downside risk and maximize returns. The expense ratio for this fund is 0.80%.
The launch follows hot on the heels of three other ETF rollouts by Horizon just last week, Horizon Core Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/STOX#BATS">STOX</a>), Horizon Dividend Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DIVN#BATS">DIVN</a>), and Horizon Managed Risk ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SFTY#BATS">SFTY</a>), bringing the firm&#8217;s ETF lineup to seven.
As fixed-income investing evolves, Horizon&#8217;s latest ETFs represent another step in providing advisers with more nimble and risk-conscious solutions in an increasingly complex market environment.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46281860/elons-america-party-etf-a-what-if-fund-of-musk-linked-stocks-like-tesla-nvidia">Elon&#8217;s America Party ETF: A What-If Fund Of Musk-Linked Stocks Like Tesla, Nvidia</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BNDY

DIVN

FLXN

SFTY

STOX

Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense

Northland Capital Markets analyst Carl Byrnes downgrades Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) from Outperform to Market Perform.

News

Downgrades

Analyst Ratings

Northland Capital Markets Downgrades Flexion Therapeutics to Market Perform

HC Wainwright &amp; Co. analyst Patrick Trucchio downgrades Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) from Buy to Neutral and lowers the price target from $25 to $10.

Price Target

HC Wainwright & Co. Downgrades Flexion Therapeutics to Neutral, Lowers Price Target to $10

BMO Capital analyst Gary Nachman downgrades Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) from Outperform to Market Perform and lowers the price target from $20 to $12.

BMO Capital Downgrades Flexion Therapeutics to Market Perform, Lowers Price Target to $12

Raymond James analyst Elliot Wilbur downgrades Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) from Strong Buy to Market Perform.

Raymond James Downgrades Flexion Therapeutics to Market Perform

Credit Suisse analyst Judah Frommer downgrades Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) from Outperform to Neutral and lowers the price target from $14 to $10.

Credit Suisse Downgrades Flexion Therapeutics to Neutral, Lowers Price Target to $10

WIIM

Flexion Therapeutics shares are trading higher after Pacira BioSciences announced it will acquire the company.

Movers

Trading Ideas

Flexion Therapeutics Shares Resume Trading; Shares Up ~68% For Session

Flexion Therapeutics, Inc. Shares To Resume Trade At 7:30 a.m. ET

<a href="https://www.globenewswire.com/Tracker?data=V228kBfVjwREsCPTeWmu_3YKDrs8Yn4TYhtOZLqjxobhSWnrUYGBgXR74qCk8uw55t6ntRi_7_QcvfmMuncYQkCyiMr74OFH4_ds51ajSbQ=" target="_blank">Pacira BioSciences, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. The CVR is payable (subject to certain terms and conditions) in the event certain sales and/or regulatory milestones are achieved, as set forth in more detail below. The transaction was unanimously approved by the board of directors of each of Pacira and Flexion.
Flexion is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis (OA), postsurgical pain and low back pain. Approved in 2017, Flexion&rsquo;s lead product, ZILRETTA&reg; (triamcinolone acetonide extended-release injectable suspension) is the first and only FDA-approved treatment for OA knee pain utilizing extended-release microsphere technology.
&ldquo;This acquisition is a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing us with a complementary commercial asset in ZILRETTA for the treatment of OA knee pain,&rdquo; said Dave Stack, chairman and chief executive officer of Pacira. &ldquo;We believe the Flexion portfolio further solidifies Pacira as a leader in opioid-sparing pain management as we continue to redefine the role of opioids as a last resort rescue medication. Importantly, this acquisition creates diversification and growth to our topline while providing what we would expect to be meaningful synergies that should result in substantial near- and long-term accretion to our cash flows and earnings.&rdquo;
&ldquo;Pacira shares our commitment to advancing non-opioid pain control and we believe it is ideally positioned to drive continued clinical and commercial success of ZILRETTA, FX201, and FX301,&rdquo; said Michael Clayman, M.D., chief executive officer and co-founder of Flexion. &ldquo;This combination with Pacira offers Flexion stakeholders excellent prospects for value creation, particularly as the contingent value rights provide the opportunity to continue to benefit from the ongoing success of Flexion&rsquo;s products and programs.&rdquo;
&ldquo;I&rsquo;d like to thank all of our employees &ndash; past and present -- for their extraordinary commitment and superb contributions that have translated into ZILRETTA, a medicine that matters, getting to increasing numbers of patients in need and to a pipeline of potentially transformative medicines,&rdquo; continued Dr. Clayman.

PCRX

Pacira BioSciences to Acquire Flexion Therapeutics For $8.50/Share In Cash Plus One Non-tradeable Contingent Value Right Worth Up To $8/Share In Cash

Flexion Therapeutics Shares Halted; News Pending

Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the&nbsp;management of osteoarthritis (OA) of the knee.1
The AAOS guidelines reflect a moderate recommendation for the use of intra-articular (IA) corticosteroids for patients with symptomatic OA of the knee. The recommendation follows a review of data from 25 studies assessing IA corticosteroids. Included in its rationale is a differential analysis of extended-release intra-articular steroid, of which ZILRETTA is the only available product, versus immediate-release IA corticosteroids, where AAOS analyses demonstrated that it can, &ldquo;be used over immediate-release corticosteroids to improve patient outcomes.&rdquo;
&ldquo;We are very pleased that the AAOS data review has determined that ZILRETTA can play a differentiated role in the treatment of OA knee pain,&rdquo; said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. &ldquo;This supports our belief that ZILRETTA is an important option for the millions of people who confront OA knee pain every year.&rdquo;
Andrew I. Spitzer, M.D., Professor of Orthopaedic Surgery, Clinical Chief, Department of Orthopaedic Surgery, Co-Director, Joint Replacement Program, Cedars-Sinai Department of Orthopaedic Surgery added, &ldquo;I believe these guidelines acknowledge the quality of data surrounding the efficacy and safety of ZILRETTA and offer healthcare providers who treat patients with knee OA added confidence to further incorporate ZILRETTA into their clinical practice.&rdquo;&nbsp;&nbsp;
The AAOS guidelines serve as an educational tool to help guide clinical treatment decisions to improve the quality and effectiveness of care and were last revised in 2013.
Indication and Select Important Safety Information for ZILRETTA
Indication:&nbsp;ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Contraindication:&nbsp;ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
<ul>
<li>Intra-articular Use Only:&nbsp;ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration.</li>
<li>Serious Neurologic Adverse Reactions with&nbsp;Epidural and Intrathecal Administration:&nbsp;Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use.</li>
<li>Hypersensitivity reactions:&nbsp;Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.</li>
<li>Joint infection and damage:&nbsp;A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment.</li>
</ul>
Adverse Reactions:&nbsp;The most commonly reported adverse reactions (incidence &ge;1%) in clinical studies included sinusitis, cough, and contusions.
Please see&nbsp;<a href="https://www.globenewswire.com/Tracker?data=urKwbGnlIqabd3DzTSmHq1mTQDWeSFvS2tUyTXilujGiCWCzx6CcEzxGsiTKcAI34SXVtojeziwg_x-qAp2NiMnyJV0sttAIft6nAuJoCQE=" target="_blank">ZilrettaLabel.com</a>&nbsp;for full Prescribing Information.

Biotech

General

Flexion Therapeutics Reports Inclusion Of ZILRETTA In American Academy Of Orthopaedic Surgeons Clinical Practice Guidelines For Mgmt. Of Osteoarthritis Of The Knee

Flexion Therapeutics shares are trading higher after the company announced the expansion of the Phase 1b trial investigating FX301 for the management of post-operative pain.

Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The company&rsquo;s decision to advance FX301 into the expansion cohort follows a review of safety data from the single ascending dose stage of the trial by an independent Safety Monitoring Committee. Subsequently, an internal review committee assessed safety, systemic exposure and efficacy data and made the decision to advance the program.
&ldquo;We are pleased that the initial findings from the four cohorts of the dose ranging data support the expansion of the trial in a selected dose,&rdquo; said&nbsp;Michael Clayman, MD, President and Chief Executive Officer of&nbsp;Flexion Therapeutics. &ldquo;We are excited to see the trial advance and look forward to sharing the results by the end of this year.&rdquo;
The single ascending dose stage of the Phase 1b trial was designed to evaluate the safety and tolerability of four dosing cohorts of 12 patients each (9 active:3 placebo). In the expansion cohort, an additional 36 patients will be randomized (1:1) to receive either FX301 at the selected dose (130 mg/low volume) or placebo to further assess the safety, tolerability, systemic exposure, and efficacy of FX301 as a single-injection analgesic nerve block adjacent to the sciatic nerve of the popliteal fossa.

Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain

<a href="https://blog.tipranks.com/2-strong-buy-penny-stocks-that-could-see-200-gains-or-more/" title="https://blog.tipranks.com/2-strong-buy-penny-stocks-that-could-see-200-gains-or-more/">https://blog.tipranks.com/2-strong-buy-penny-stocks-that-could-see-200-gains-or-more/</a>

Flexion Therapeutics Shares See Volume; Traders Circulate TipRanks Report Titled '2 "Strong Buy" Penny Stocks That Could See 200% Gains (Or More)'

&nbsp;Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in&nbsp;<a href="https://www.globenewswire.com/Tracker?data=LHDhvo9PfWLnhavWC1Y2KotO9bMGjEufaL1Qyl5O8hDMKb1bZVkX5T6qBEIPwdC7S2echyP9aX_IsEtobcx9CcLreclWHRdHxfOv-_vE8Sp_Jx8x_WwmbLl9o4kGk_U8puHMeeeCfH9g3le-sus3XpNPO9NzRlnt6GBQEO8q_RfFcyESmIau6-dnsize8fW2GjxodP2SNYcYLJcINclhrBez3Osgy9tjPvN3khdbMvQ-qqKXHfEMbQLn6chTcM7YlNIYigX_m8M4pnZ3XhEmfkTNV2U-NL0EszO2c29qFHSpX8jJm0Bu_pCCtaUfrGPNyQwvm0dysb2bZiKNoM8cXNotlBH7oiIcbix_sv4nCKs=" target="_blank">Drugs in R&amp;D</a>.&nbsp;The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension (TAcs) and assessed the safety and general tolerability of ZILRETTA in osteoarthritis (OA) of the shoulder.
&quot;Shoulder OA pain can significantly impact a person&#39;s quality of life; however, there are currently no FDA approved pharmacologic treatments for this common and debilitating condition,&quot; said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. &quot;The publication of these data demonstrate that ZILRETTA&#39;s release profile in the shoulder is consistent with what we observed in the knee, and they strengthen our confidence in the potential for our product to make a meaningful difference in the lives of people confronting OA shoulder pain.&quot;
In the Phase 2, randomized, open-label, single-dose study, 25 adults with moderate to severe shoulder OA received a single ultrasound-guided intra-articular (IA) injection of either ZILRETTA (n=12) or TAcs (n=13). All patients were evaluated for 12 weeks post-injection. PK and safety profiles of ZILRETTA were similar to those reported in Phase 3 studies of patients with knee OA. Plasma PK findings from this study were also consistent with the extended release of triamcinolone acetonide (TA) within the synovial fluid following an IA injection of ZILRETTA in the knee. Extended release may enable sustained analgesic effect in the shoulder.
Key topline results include:
<ul>
<li>In patients treated with ZILRETTA the total and maximal exposure to TA was approximately two-thirds lower when compared to TAcs.
<ul>
<li>Following an injection of ZILRETTA, plasma TA concentration peaked at four hours post-injection, was sustained over the ensuing 24 hours, and then declined slowly during the remainder of the study.</li>
</ul>
</li>
<li>There were no serious adverse events (AEs) and no AEs led to study discontinuation in either treatment group. 
	&nbsp;</li>
</ul>
Flexion plans to initiate a registration trial to further investigate ZILRETTA in shoulder OA later this year.
ZILRETTA is currently approved for the management of OA pain of the knee. ZILRETTA is not approved as a treatment for shoulder OA.
Indication and Select Important Safety Information for ZILRETTA
Indication:&nbsp;ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Contraindication:&nbsp;ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
<ul>
<li>Intra-articular Use Only:&nbsp;ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration.</li>
<li>Serious Neurologic Adverse Reactions with&nbsp;Epidural and Intrathecal Administration:&nbsp;Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use.</li>
<li>Hypersensitivity reactions:&nbsp;Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.</li>
<li>Joint infection and damage:&nbsp;A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment.</li>
</ul>
Adverse Reactions:&nbsp;The most commonly reported adverse reactions (incidence &ge;1%) in clinical studies included sinusitis, cough, and contusions.
Please see&nbsp;<a href="https://www.globenewswire.com/Tracker?data=gMZ4HEgiD8KE_RkD5isUsGGqwKy6nrZLps0IKJd2BVJWpqgLO1u_CpuX_ZRYM13TeDrBcMKSQc5W5qOI9GTWMpWr1Fb0E1td1pVKLLa7cIM=" target="_blank">ZilrettaLabel.com</a>&nbsp;for full Prescribing Information.

Flexion Therapeutics Announces Publication Of Results From Phase 2 Pharmacokinetics (PK) And Safety Study Of ZILRETTA In Shoulder Osteoarthritis (OA)

Goldman Sachs maintains Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) with a Neutral and lowers the price target from $8 to $6.

Goldman Sachs Maintains Neutral on Flexion Therapeutics, Lowers Price Target to $6

Needham analyst Serge Belanger maintains Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) with a Buy and lowers the price target from $20 to $18.

Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $18

Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) reported quarterly losses of $(0.44) per share. This is a 42.11 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $28.18 million which missed the analyst consensus estimate of $29.01 million by 2.88 percent. This is a 82.35 percent increase over sales of $15.45 million the same period last year.

Earnings

Flexion Therapeutics Q2 EPS $(0.44) Up From $(0.76) YoY, Sales $28.18M Miss $29.01M Estimate

Credit Suisse analyst Judah C Frommer maintains Flexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) with a Outperform and lowers the price target from $17 to $14.

Comments

Horizon Funds Horizon Flexible Income ETF

Notizie

Ultime notizie per Horizon Funds Horizon Flexible Income ETF (BATS:FLXN)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO